Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Levetiracetam (SIB-S1) 是一种化学增敏剂,增强 Temozolomide 对胶质母细胞瘤干细胞增殖和凋亡的影响。它调节 HDAC 水平,最终使 MGMT 沉默从而提高 Temozolomide 的有效性。它是一种抗癫痫药,可结合突触小泡蛋白 SV2A。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 337 | 现货 | ||
50 mg | ¥ 581 | 现货 | ||
100 mg | ¥ 919 | 现货 | ||
200 mg | ¥ 1,390 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 627 | 现货 |
产品描述 | Levetiracetam (SIB-S1) is a relatively unique anticonvulsant that is typically used in combination with other antiepileptic medications for partial onset seizures. Levetiracetam has been linked to rare instances of serum aminotransferase and alkaline phosphatase elevations during treatment and to rare cases of clinically apparent drug induced liver disease. |
体外活性 | 对完全杏仁核刺激的大鼠,即颞叶癫痫模型,Levetiracetam对病灶性和二次全身性发作表现出有效的抗痉挛活性.腹腔注射5.4 mg/kg到96 mg/kg Levetiracetam抑制声源性惊厥易感大鼠乱跑和强直阵挛性惊厥,这种作用具有剂量依赖性.腹腔注射13 mg/kg,27 mg/kg或54 mg/kg Levetiracetam,剂量依赖性抑制反复杏仁核刺激诱发的癫痫发作.17 mg/kg Levetiracetam对声音诱发的小鼠阵挛性惊厥产生有效的抑制作用. |
体内活性 | 在新鲜离体的大鼠CA1海马神经元中,Levetiracetam不可逆抑制平均大约18%的高电压激活的(HVA)钙离子电流。Levetiracetam选择性抑制CA1锥体海马神经元的N型Ca2+通道,逆转海马神经元中DMCM对GABA引起的电流的抑制作用。 |
激酶实验 | EDTA plasma (20 μL) is diluted with 30 μL of DPP-4 assay buffer (100 mM Tris and 100 mM NaCl, adjusted to pH 7.8 with HCl) and mixed with 50 μL of H-Ala-Pro-7-amido-4-trifluoromethylcoumarin. The 200 mM stock solution in dimethylformamide is diluted 1:1000 with water to yield a final concentration of 100 μM. The plate is incubated at room temperature for 10 min, and fluorescence in the wells is determined by using a Victor 1420 Multilabel Counter at an excitation wavelength of 405 nm and an emission wavelength of 535 nm. For the detection of DPP-4 activity in wound lysates, 100 μg of protein from the respective wound lysates are used instead of 20 μL of plasma. Active GLP-1 is also detected from 100 μg of respective wound tissue samples and analyzed by using the Mouse/Rat Total Active GLP-1 Assay Kit. |
别名 | 左乙拉西坦, UCB L059, SIB-S1 |
分子量 | 170.21 |
分子式 | C8H14N2O2 |
CAS No. | 102767-28-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 17 mg/mL (100 mM)
H2O: 17 mg/mL (100 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / H2O | 1 mM | 5.8751 mL | 29.3755 mL | 58.751 mL | 146.8774 mL |
5 mM | 1.175 mL | 5.8751 mL | 11.7502 mL | 29.3755 mL | |
10 mM | 0.5875 mL | 2.9375 mL | 5.8751 mL | 14.6877 mL | |
20 mM | 0.2938 mL | 1.4688 mL | 2.9375 mL | 7.3439 mL | |
50 mM | 0.1175 mL | 0.5875 mL | 1.175 mL | 2.9375 mL | |
100 mM | 0.0588 mL | 0.2938 mL | 0.5875 mL | 1.4688 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Levetiracetam 102767-28-2 Chromatin/Epigenetic Membrane transporter/Ion channel Metabolism Others Calcium Channel DNA Methyltransferase DNMTs chemosensitizer vesicle inhibit antiepileptic Temozolomide HDA 左乙拉西坦 Inhibitor SV2A UCB L-059 synaptic protein DNA MTases MGMT UCB L059 UCB L 059 SIB-S1 glioblastoma apoptosis inhibitor